Get Your Own businessabc Wiki

Boost credibility, visibility, and discoverability

Last Updated: 2026

Veracyte

Rank#3699

Market Cap3.78B

CountryUnited States

Summary

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

History

Veracyte was founded in 2008 to pursue its proprietary Afirma Genomic Sequencing Classifier (GSC) technology, which pioneered a new field of molecular cytology. Dr. Brett Circe and Dr. Tom Weis were the original founding scientists behind the technology.

Mission

Veracyte's mission is to make diagnostic information accessible and actionable to improve patient care and reduce costs of health care.

Vision

Veracyte's vision is to create a world of personalized care where genomic information is used to inform and enhance medical decision-making and uncover new treatments.

References

https://in.investing.com/equities/veracyte-inc

https://finance.yahoo.com/quote/VCYT/profile?p=VCYT

https://www.crunchbase.com/organization/veracyte

https://sec.report/CIK/0001384101

https://companiesmarketcap.com/

https://www.veracyte.com

Leadership team

Ms. Bonnie H. Anderson (Co-Founder & Exec. Chairwoman)

Mr. Marc A. Stapley (CEO & Director)

Ms. Rebecca Chambers (Exec. VP & CFO)

Products / Services

Biotechnology, Health Care, Health Diagnostics

Number of Employees

500 - 1000

Address

South San Francisco, California, United States

Established

2006-01-01

Company Registration

SEC CIK number: 0001384101

Revenue

100M - 500M

Traded as

VCYT

Website

https://www.veracyte.com

Social Media

Last Updated: 2026

Get Your Own businessabc Wiki

Boost credibility, visibility, and discoverability

Learn More

Last Updated: 2026

Veracyte

Rank#3699

Market Cap3.78B

CountryUnited States

Summary

History

Mission

Veracyte's mission is to make diagnostic information accessible and actionable to improve patient care and reduce costs of health care.

Vision

Veracyte's vision is to create a world of personalized care where genomic information is used to inform and enhance medical decision-making and uncover new treatments.

References

https://in.investing.com/equities/veracyte-inc

https://finance.yahoo.com/quote/VCYT/profile?p=VCYT

https://www.crunchbase.com/organization/veracyte

https://sec.report/CIK/0001384101

https://companiesmarketcap.com/

https://www.veracyte.com

Leadership team

Ms. Bonnie H. Anderson (Co-Founder & Exec. Chairwoman)

Mr. Marc A. Stapley (CEO & Director)

Ms. Rebecca Chambers (Exec. VP & CFO)

Products / Services